$INCY

Tray Thomas sold $200K of INCY

Tray Thomas (Principal Accounting Officer) sold 2,051 shares of INCYTE CORP (INCY) at $97.35 ($0.20M total) on 2026-05-26 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Tray Thomas
Published May 28, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 8:47 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$INCY
Neutral
medium confidence
Mentioned
$INCY
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INCYNeutralLow
01

Why it matters

The only new information is the disclosed sale size, price, and post-transaction holdings under a 10b5-1 plan; it does not include guidance, litigation, or operational updates.

02

Market read

Traders may note the insider sale as a sentiment datapoint, but the 10b5-1 structure makes it unlikely to drive a durable repricing by itself.

03

What to watch

Insider sales can be offset by other insider buys or option exercises not shown here; also, the filing does not reveal intent beyond the pre-arranged plan.

Relevance 3/10Novelty 3/10Timing: filed 2026-05-28, transaction dated 2026-05-26

Background

This is an SEC Form 4 insider transaction disclosure for Incyte, reported by Tray Thomas (Principal Accounting Officer).

Company-level read

Ticker impact

$INCYNeutralMedium confidence
Context

Incyte Form 4 shows Tray Thomas sold 2,051 shares at $97.35 on a 10b5-1 plan, disclosing $199,664.85 in insider sales.

Expected impact

Low near-term impact; any reaction is likely muted unless paired with other new fundamentals.

Evidence & confidence

The filing is a primary-source Form 4 and is time-stamped, but the transaction is explicitly under a pre-arranged 10b5-1 plan, which typically reduces interpretive weight.

Market effects

No clear sector read-through from a single 10b5-1 insider sale.

None indicated.

None indicated.

Counterpoint

The sale could be purely liquidity-driven under the 10b5-1 schedule and should not be treated as bearish signal.

Key entities

  • Incyte Corp

    Subject of the Form 4 insider transaction disclosure.

  • Tray Thomas

    Principal Accounting Officer who sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

HC Wainwright & Co. reiterates Buy rating on Incyte, $152 price target

HC Wainwright & Co. reiterated a Buy rating on Incyte (INCY) with a $152 price target, suggesting a 36.5% upside from the Oct 12 close. The firm cited strong pipeline potential, particularly for drug INCB161734, with a 69% response rate in untreated patients and projected annual sales of $700 million in the U.S. G12D pancreatic cancer market.

$SNDXHighAI 8/10

Syndax shares fall as lung fibrosis drug fails trial

Syndax Pharma's shares fell 17% pre-market after abandoning its IPF drug axatilimab, which failed a phase 2 trial. The drug, partnered with Incyte, is approved for cGVHD as Niktimvo. Incyte's shares also dipped slightly. Syndax reported $152M in 2025 revenue, with $115M in the first half of 2026.

$INCYMed

Incyte (INCY) Won New Approvals, Is The Pullback A Cheap Entry?

Incyte (INCY) received U.S. approval for Atebrioz and Brazil's expedited approval for NIKTIMVO. Shares are down 6.52% in 7 days and 10.50% in 30 days, but up 11.85% year-to-date and 32.86% in 1 year. The stock trades 14% below the average analyst price target. Incyte's 2026 guidance projects total net sales of $5.13B-$5.26B and Opzelura net sales of $1.05B-$1.10B. Analysts value the stock at $128.48, while a DCF model values it at $93.58.